Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anurag S. Srivastava"'
Autor:
Carolyn A. Weigelt, Sha Li, David Marcoux, Georgia Cornelius, Qihong Zhao, Mary Ellen Cvijic, John E. Macor, Jingwu Duan, Melissa Yarde, Muthalagu Vetrichelvan, David J. Shuster, Qingjie Liu, Richard Rampulla, Kim W. McIntyre, Mary T. Obermeier, Shiuhang Yip, Purnima Khandelwal, Sureshbabu Vishwakrishnan, Anuradha Gupta, Virna Borowski, Peng Li, Kevin Stefanski, Sridharan Ramlingam, Myra Beaudoin-Bertrand, Nageswara Maddala, Sridhar Vanteru, Percy H. Carter, Arvind Mathur, Aberra Fura, Max Ruzanov, John Hynes, Dauh-Rurng Wu, Jinhong Wang, Luisa Salter-Cid, John S. Sack, Cornelius Lyndon A M, Anurag S. Srivastava, Robert J. Cherney, Kumaravel Selvakumar, Mushkin Basha, Arun Kumar Gupta, Douglas G. Batt, Rex Denton, Sukhen Karmakar, Qing Shi, Ananta Karmakar, Naveen Manjunath, Javed Khan, Jenny Xie, Joseph A. Tino, T. G. Murali Dhar
Publikováno v:
Journal of Medicinal Chemistry. 62:9931-9946
RORγt is an important nuclear receptor that regulates the production of several pro-inflammatory cytokines such as IL-17 and IL-22. As a result, RORγt has been identified as a potential target for the treatment of various immunological disorders su
Autor:
Mary Ellen Cvijic, Andrew J. Tebben, Jian Pang, Mary F. Malley, Ruowei Mo, Joseph B. Santella, Songmei Xu, Qihong Zhao, Douglas G. Batt, Jing Chen, Anne Rose, Bei Wang, Hong Shi, Marta Dabros, Anurag S. Srivastava, Percy H. Carter, Purnima Khandelwal, Yang Michael G, Gardner Daniel S, Gregory D. Brown, Sandhya Mandlekar, Michael Galella, Rulin Zhao, Zili Xiao, John V. Duncia, Sarah C. Traeger, Joel C. Barrish, Robert J. Cherney, Soo S. Ko
Publikováno v:
ACS Medicinal Chemistry Letters. 10:300-305
[Image: see text] We encountered a dilemma in the course of studying a series of antagonists of the G-protein coupled receptor CC chemokine receptor-2 (CCR2): compounds with polar C3 side chains exhibited good ion channel selectivity but poor oral bi
Autor:
Soo S. Ko, James Kempson, Yingru Zhang, Tracy L. Taylor, Kim W. McIntyre, James R. Burke, Luisa Salter-Cid, Shiuhang Yip, Celia D’Arienzo, Aberra Fura, Stacey Skala, Joseph A. Tino, Jun Dai, Chunlei Wang, Joel C. Barrish, Michael Galella, Kathleen M. Gillooly, Bei Wang, Dauh-Rurng Wu, Lorell Discenza, Xiaoping Hou, Arvind Mathur, Richard Rampulla, Dawn Sun, Scott H. Watterson, Mary T. Obermeier, Percy H. Carter, Mark A. Pattoli, Anurag S. Srivastava, Lihong Cheng, Rulin Zhao, Peng Li, Claudine Pulicicchio, Joseph Pawluczyk, Rodney Vickery
Publikováno v:
ACS Med Chem Lett
[Image: see text] Bruton’s tyrosine kinase (BTK) has been shown to play a key role in the pathogenesis of autoimmunity. Therefore, the inhibition of the kinase activity of BTK with a small molecule inhibitor could offer a breakthrough in the clinic
Autor:
Qingjie Liu, Mary T. Obermeier, John S. Sack, Carolyn A. Weigelt, Georgia Cornelius, Percy H. Carter, David J. Shuster, Luisa Salter-Cid, Aberra Fura, Virna Borowski, Jingwu Duan, Purnima Khandelwal, Qing Shi, Robert J. Cherney, Cornelius Lyndon A M, Jinhong Wang, Jenny Xie, Max Ruzanov, Kevin Stefanski, Rex Denton, T. G. Murali Dhar, David Marcoux, Shiuhang Yip, Melissa Yarde, Douglas G. Batt, Javed Khan, Joseph A. Tino, Qihong Zhao, Anurag S. Srivastava, Arvind Mathur, Mary Ellen Cvijic, John E. Macor, Sha Li, Dauh-Rurng Wu
Publikováno v:
ACS Med Chem Lett
[Image: see text] Novel tricyclic analogues were designed, synthesized, and evaluated as RORγt inverse agonists. Several of these compounds were potent in an IL-17 human whole blood assay and exhibited excellent oral bioavailability in mouse pharmac
Autor:
Carolyn A. Weigelt, Xiaomei Gu, Stacey Skala, Paul Davies, Jenny Xie, John S. Sack, T. G. Murali Dhar, Melissa Yarde-Chinn, James Neels, Michael A. Poss, Stefan Ruepp, Robert J. Cherney, Christine Goldstein, Joseph A. Tino, Luisa Salter-Cid, Kevin Stefanski, Vojkan Susulic, Rajeev S. Bhide, Xiaoxia Yang, Anurag S. Srivastava, Zheming Ruan, Lan-Ying Qin, Cornelius Lyndon A M, Ruth Bosnius
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:855-861
As demonstrated in preclinical animal models, the disruption of PI3Kδ expression or its activity leads to a decrease in inflammatory and immune responses. Therefore, inhibition of PI3Kδ may provide an alternative treatment for autoimmune diseases,
Autor:
Dezhi Xing, Carolyn A. Weigelt, Luisa Salter-Cid, Pirama Nayagam Arunachalam, Rodney B.W. Smith, Ling Li, Melissa Yarde, Jodi K. Muckelbauer, Jonathan Lippy, Mary Ellen Cvijic, Sidney Pitt, John S. Sack, Thatipamula Rp, Michael A. Poss, Paul Levesque, Robert J. Cherney, Ipsit Kundu, David Marcoux, Gary L. Schieven, Arvind Mathur, Qingjie Liu, Zheming Ruan, Rosemary Zhang, R M Fancher, Shweta Padmanabhan, Scott H. Watterson, Qing Shi, Mary T. Obermeier, Anurag S. Srivastava, Anuradha Gupta, Douglas G. Batt, James Neels, Joseph A. Tino, Kevin Stefanski, Percy H. Carter, Macor John E, John Hynes, Myra Beaudoin-Bertrand, Hao Lu, Kim W. McIntyre, Stacey Skala, Aberra Fura, Lan-Ying Qin, Cornelius Lyndon A M, James Hennan, Richard Rampulla, Bogdan Sleczka, Jenny Xie, Kallem Rajareddy, Jie Pan, Christine B. Goldstine, Hua Gong, Qian Ruan, Kathleen M. Gillooly, Donna L. Pedicord, Jingsong Fan, Rajeev S. Bhide, Stefan Ruepp
Publikováno v:
Journal of medicinal chemistry. 60(12)
PI3Kδ plays an important role controlling immune cell function and has therefore been identified as a potential target for the treatment of immunological disorders. This article highlights our work toward the identification of a potent, selective, a
Autor:
Hai-Yun, Xiao, Scott H, Watterson, Charles M, Langevine, Anurag S, Srivastava, Soo S, Ko, Yanlei, Zhang, Robert J, Cherney, Wei-Wei, Guo, John L, Gilmore, James E, Sheppeck, Dauh-Rurng, Wu, Peng, Li, Duraisamy, Ramasamy, Piramanayagam, Arunachalam, Arvind, Mathur, Tracy L, Taylor, David J, Shuster, Kim W, McIntyre, Ding-Ren, Shen, Melissa, Yarde, Mary Ellen, Cvijic, Anthony M, Marino, Praveen V, Balimane, Zheng, Yang, Dana M, Banas, Georgia, Cornelius, Celia J, D'Arienzo, Bethanne M, Warrack, Lois, Lehman-McKeeman, Luisa M, Salter-Cid, Jenny, Xie, Joel C, Barrish, Percy H, Carter, Alaric J, Dyckman, T G Murali, Dhar
Publikováno v:
Journal of medicinal chemistry. 59(21)
Fingolimod (1) is the first approved oral therapy for the treatment of relapsing remitting multiple sclerosis. While the phosphorylated metabolite of fingolimod was found to be a nonselective S1P receptor agonist, agonism specifically of S1P